Efficacy and Safety of MEDI6570 in Patients with a History of Myocardial Infarction - GOLDILOX

Study identifier:D4920C00002

ClinicalTrials.gov identifier:NCT04610892

EudraCT identifier:2020-000840-75

CTIS identifier:N/A

Study Complete

Official Title

A Phase IIB, Randomized, Double blinded, Placebo controlled, Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction and Persistent Inflammation

Medical condition

Coronary Heart Disease (CHD)

Phase

Phase 2

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

423

Study type

Interventional

Age

21 Years - n/a

Date

Study Start Date: 04 Nov 2020
Primary Completion Date: 08 Nov 2023
Study Completion Date: 08 Nov 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Thrombolysis in Myocardial Infarction (TIMI) Study Group

Inclusion and exclusion criteria